Skip to main content
FACULTY PROFILE STYLESHEET: do not remove this block

Alexandra C. Newton, Ph.D.
Distinguished Professor of Pharmacology
Director, Cell Signaling San Diego

Research Interests

Our lab focusses on the molecular mechanisms by which disruption of the balance between phosphorylation and dephosphorylation drives disease. We focus in particular on understanding how deregulated signaling by protein kinases and phosphatases is involved in cancer vs degenerative diseases. We are particularly interested in protein kinase C and related kinases such as Akt, and the protein phosphate PH domain Leucine rich repeat Protein Phosphatase PHLPP (pronounced ‘flip’).

 

Selected Publications

Antal, C. E., Hudson, A. M., Kang, E., Zanca, C., Wirth, C., Stephenson, N. L., Trotter, E. W., Gallegos, L. L., Miller, C. J., Furnari, F. B., Hunter, T., Brognard, J., Newton, A. C. (2015). Cancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor. Cell 160, 489-502.

Callender JA, Yang Y, Lordén G, Stephenson NL, Jones AC, Brognard J, Newton A.C. Protein kinase Cα gain-of-function variant in Alzheimer’s disease displays enhanced catalysis by a mechanism that evades down-regulation. Proc Natl Acad Sci U S A. (2018). Jun 12;115(24):E5497-E5505.

Kajimoto, T., Caliman, A. D., Tobias, I. S., Okada, T., Pilo C. A., Van, A. N., McCammon, A. J., Nakamura, S. I., Newton, A.C. Activation of atypical protein kinase C by sphingosine 1-phosphate revealed by an aPKC-specific activity reporter. Sci Signal. (2019). Jan 1;12(562)

Baffi, T. R., Van, A. N., Zhao, W., Mills, G. B., and Newton, A. C. (2019) Protein Kinase C Quality Control by Phosphatase PHLPP1 Unveils Loss-of-Function Mechanism in Cancer. Mol. Cell, 74, 378-392.

Kawashima, A. T., Wong, C., King, C.C., Lara-Gonzalez, P., Desai, A., Gingras, A.C., and Newton, A. C. (2021). The PHLPP1 N-Terminal Extension is a Mitotic Cdk1 Substrate and Controls and Interactome Switch. Mol. Cell Bio. 41 (3):e00333-20

Baffi TR, Lordén G, Wozniak JM, Feichtner A, Yeung W, Kornev AP, King CC, Del Rio JC, M., Limaye, A. J., Wayland, Y., Bogomolovas, J., Gould, C. M., Chen, J., Kannan, N., Kennedy, E. J., Gonzalez, D. J., Stefan, E., Taylor, S. S., and Newton, A. C. (2021). mTORC2 Controls PKC and Akt via Phosphorylation of a Conserved TOR-Interaction Motif. Sci. Sign., 14, eabe4509.

 

Divisions

Cancer Biology
Neuropharmacology & Neurological Disorders

Programs

Biochemical, Biophysical and Structural Pharmacology Program
Signaling & Molecular Pharmacology